Related Experiment Video
Updated: May 15, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
The effectiveness of interferon-alpha subtypes alternation for metastasis from renal cell carcinoma
Yoshifumi Kadono1, Sotaro Miwa, Takashi Shima
1Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa. yskadono@yahoo.co.jp
Abstract:
Interferon-alpha (IFN-α) has been used in systemic treatment for metastatic renal cell carcinoma (mRCC). IFN-α has at least 14 subtypes, each of which has different biological activity. There have been reports that mRCC resistant to an IFN-α treatment responded to another IFN-α subtype. This study was performed to evaluate the effectiveness of alternation of different IFN-α subtypes for mRCC that did not respond to initial IFN-α treatment. In our department and associated institutions, alternating therapy of IFN-α was provided for 15 initial IFN-α refractory mRCC cases from June 2005 to September 2008. Among the 15 patients, the effects of alternating IFN-α therapy were as follows: complete response (CR), 0 cases; partial response (PR), 1 case; stable disease (SD), 3 cases; progressive disease (PD), 11 cases. The response rate (CR+PR) was 7% and disease control rate (CR+PR+SD) was 27%. No severe side effects were observed in any of these cases. The PR case is still in PR 21 months after alternating IFN-α therapy. Among the three SD cases, one has continued SD for 14 months and the other for 12 months. Alternating IFN-α therapy for mRCC can be attempted even if other cytokines are not effective.
Insights
For metastatic renal cell carcinoma (mRCC) resistant to initial treatment, alternating interferon-alpha (IFN-α) subtypes showed a 7% response rate. This approach offers a potential option when other cytokine therapies are ineffective.
Area of Science:
- Oncology
- Immunotherapy
- Renal Cell Carcinoma Research
Background:
- Interferon-alpha (IFN-α) is a systemic treatment for metastatic renal cell carcinoma (mRCC).
- IFN-α comprises numerous subtypes with distinct biological activities.
- Previous reports suggest cross-subtype responsiveness in IFN-α-refractory mRCC.
Purpose of the Study:
- To evaluate the efficacy of alternating different IFN-α subtypes in mRCC patients.
- To assess outcomes for mRCC refractory to initial IFN-α therapy.
Main Methods:
- A cohort of 15 patients with initial IFN-α refractory mRCC received alternating IFN-α subtype therapy.
- Treatment was administered between June 2005 and September 2008.
- Response evaluation included complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD).
Main Results:
- The overall response rate (CR+PR) was 7% (1 PR).
- The disease control rate (CR+PR+SD) was 27% (1 PR, 3 SD).
- One patient maintained a partial response for 21 months; three patients achieved stable disease for 12-14 months. No severe side effects were noted.
Conclusions:
- Alternating IFN-α subtype therapy can be considered for mRCC patients refractory to initial IFN-α treatment.
- This strategy may offer a viable therapeutic option when other cytokine treatments have failed.
- The observed durable responses in a subset of patients warrant further investigation.
More Related Videos
10:00High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
